Drug-induced paraparotid fat deposition in patients with HIV: Case reports

Journal of the American Dental Association

Volumn 139, Issue 2, 2008, Pages 152-157

  Mandel, Louis ^a,b   Alfi, David ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b New York Presbyterian Hospital ^*  (United States)

Author keywords

Highly active antiretroviral therapy; Lipodystrophy; Lipodystrophy syndrome; Paraparotid fat

Indexed keywords

EID: 39749114434     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2008.0130     Document Type: Article

References (30)

1. Dubé MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997;350(9079):713-4.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(7):F51-8.
3. Rakotoambinina B, Médioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndrome and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr 2001;27(5):443-9.
4. Gold DR, Annino DJ Jr. HIV-associated cervicodorsal lipodystrophy: etiology and management. Laryngoscope 2005;115(5):791-5.
5. Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: the price of success. JAMA 2006;296(7):844-54.
6. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14(1):37.
7. Chen D, Misra A, Garg A. Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002;87(11):4845-56.
8. Mori A, Lo Russo G, Agostini T, Pattarino J, Vichi F, Dini M. Treatment of human immunodeficiency virus-associated facial lipoatrophy with lipofilling and submalar silicone implants. J Plast Reconstr Aesthet Surg 2006;59(11):1209-16.
9. Woolley IJ, Mijch AM, Carter VM, Archer B, Hoy JF. Anterior neck fat deposition in lipodystrophy syndrome; a new variant on a theme? AIDS 2003;17(12):1857-8.
10. Dinges WL, Chen D, Snell PG, Weatherall PT, Peterson DM, Garg A. Regional body fat distribution in HIV-infected patients with lipodystrophy. J Investig Med 2005;53(1):15-25.
11. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci 2005;26(2):88.
12. Chanu B, Valensi P. Lipid disorders in patients with HIV-induced diseases. Presse Med 2005;34(15):1087-94.
13. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitiors. AIDS 1999;13(10):F63-70.
14. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosigliatazone in HIV lipodystrophy: a randomized, controlled trial. Ann Int Med 2004;140(10):786-94.
15. Lee GA, Seneviratne T, Noor MA, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004;18(4):641-9.
16. Walli R, Herfort O, Michi GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12(15):F167-73.
17. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353(9170):2093-9.
18. Joly V, Flandre P, Meifreddy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of substudy from a comparative trial. AIDS 2002;16(18):2447-54.
19. Galli M, Cozzi-Lepri A, Ridolfo AL, et al. Incidence of adipose tissue alterations in front-line antiretroviral therapy: the LipolCoNA Study. Arch Intern Med 2002;162(22):2621-8.
20. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev 2006;8(4):191-203.
21. Domingo P, Sambeat MA, Pérez A, Ordõnez J, Rodriguez J, Vazquez G. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination of antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor. Antivir Ther 2003;8(3):223-31.
22. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357(9256):592-8.
23. van der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001;15(7):847-55.
24. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001;6(1):9-20.
25. Nolan D, John M, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis. Antivir Ther 2001;6(3):145-60.
26. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89(3):299-304.
27. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to ahacavir: the MITOX Extension Study. AIDS 2004;18(7):1029-36.
28. Moyle G. Metabolic issues associated with protease inhibitors. J Acquir Immune Defic Syndr 2007;45(supplement 1):S19-26.
29. Sutinen J, Hakkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy: a randomized double-blind placebo-controlled study. Antivir Ther 2003;8(3):199-207.
30. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004;363(9407):429-38.